In addition to the above-mentioned three classic targets, a couple of other tumor biomarkers such as transferrin receptor (TfR), death receptor 5 (DR5), prostate stem cell antigen (PSCA), and mucin-1 (MUC1) have also been utilized as targets of mAb-decorated nanoparticles for cancer therapy.183–186 mAb-conjugated nanoparticles designed for targeted delivery of imaging/therapeutic agents to cancer cells have shown great potentials to revolutionize the future of cancer theranostics, owing to their superior efficacy and minimized off-target effects. The gene discussed is PSCA; the disease is cancer.